Revance Therapeutics, Inc.
$ 3.65
0.00%
12 Jun - close price
- Market Cap 381,024,000 USD
- Current Price $ 3.65
- High / Low $ 3.65 / 3.65
- Stock P/E N/A
- Book Value -1.55
- EPS -3.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -20.97 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Analyst Target Price
$9.47
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 | 2022-11-08 | 2022-08-09 | 2022-05-10 | 2022-02-28 |
| Reported EPS | -0.37 | -0.36 | -0.58 | -0.62 | -1.63 | -0.8 | -0.74 | -0.95 | -1.17 | -0.88 | -0.94 | -0.93 |
| Estimated EPS | -0.38 | -0.53 | -0.75 | -0.72 | -0.85 | -0.78 | -0.7 | -0.95 | -0.89 | -0.86 | -0.83 | -1 |
| Surprise | 0.01 | 0.17 | 0.17 | 0.1 | -0.78 | -0.02 | -0.04 | 0 | -0.28 | -0.02 | -0.11 | 0.07 |
| Surprise Percentage | 2.6316% | 32.0755% | 22.6667% | 13.8889% | -91.7647% | -2.5641% | -5.7143% | 0% | -31.4607% | -2.3256% | -13.253% | 7% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVNC
2026-06-08 21:41:00
Revance Therapeutics, Inc. (RVNC) currently trades at $3.65, with analysts holding a consensus "Hold" rating based on 22 analysts, including 10 buys, 12 holds, and 0 sells. The 12-month average price target is $20.78, representing a significant potential upside of +469.3% from the current price. Recent analyst actions include several downgrades from firms like Barclays, Needham, and Guggenheim.
2026-06-02 10:41:10
Faruqi & Faruqi, LLP is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ: RVNC) and reminds investors of the February 8, 2022, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Revance Therapeutics made false or misleading statements regarding quality control deficiencies at its manufacturing facility, which impacted the FDA approval process for its DAXI product. Investors who suffered losses exceeding $100,000 between November 25, 2019, and October 11, 2021, are encouraged to contact the firm.
2026-05-11 16:20:00
Investors who bought Revance Therapeutics Inc. securities (common stock or 1.75% fixed coupon convertible senior unsecured notes) between February 29, 2024, and February 6, 2025, may be eligible for a cash payment from a $17 million class action settlement. The lawsuit alleged that Revance and its executives made misleading statements and omitted material facts regarding the company's relationship with Teoxane SA and the merger with Crown Laboratories Inc., artificially inflating security prices. The deadline to file a claim is August 28, 2026.
2026-05-01 16:39:40
Faruqi & Faruqi, LLP is investigating potential securities claims against Revance Therapeutics, Inc. and reminds investors of the February 8, 2022 deadline to seek the role of lead plaintiff. The investigation stems from allegations that Revance Therapeutics made false or misleading statements regarding quality control deficiencies at its manufacturing facility, leading to issues with FDA approval for its DAXI product and subsequent significant drops in stock price. Investors who suffered losses exceeding $100,000 between November 25, 2019, and October 11, 2021, are encouraged to contact the firm.
2026-04-08 20:09:58
This article provides a comprehensive overview of Revance Therapeutics (RVNC) stock, focusing on its innovative neuromodulator Daxxify, financial performance, and market position within the competitive aesthetics industry. It highlights the company's core products, market capitalization, institutional ownership, and competitive landscape, including major rivals like AbbVie. The article also touches upon regulatory considerations, analyst ratings, and the future outlook for RVNC stock in the expanding global aesthetics market.
2026-03-28 16:30:27
The U.S. hyaluronic acid based dermal fillers market, valued at USD 1.53 billion in 2022, is projected to grow at a CAGR of 8.2% during the forecast period due to increasing awareness of cosmetic procedures and growing per capita income. Key factors driving market growth include the rising demand for minimally invasive cosmetic procedures among young people and the aging population, coupled with continuous product innovation and FDA approvals. However, the market faces restraints from the availability of alternative dermal fillers and concerns about temporary results or side effects.
